First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: Results from LEAP-003.

Authors: Jun Guo, Xiaoshi Zhang, Di Wu, Lu Si, Ya Ding, Zhiguo Luo, Xiubao Ren, Zhengyun Zou, Yu Chen, Meiyu Fang, Ke Li, Quanli Gao, Hongming Pan, Chinyere E Okpara, Wei Wang, Shanshan Chen, Mizuho Fukunaga-Kalabis, Ana Maria Arance

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.9553

Source: Full article

---

Abstract

9553